Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1180-1185 , August 2010

Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury

Presented in abstract form at the American Society of Hematology Annual Meeting, San Francisco, California, December 2008 and at the American Society of Blood and Marrow Transplantation Annual Meeting, Tampa, Florida, February 2009.

  • Corey Cutler

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • Corresponding Author InformationCorrespondence and reprint requests: Corey Cutler, MD MPH FRCP(C), Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, D1B13, Boston, MA 02115.
    • ,
  • Haesook T. Kim

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Shaké Ayanian

      Affiliations

    • Laboratory Medicine, Children's Hospital Boston, Boston, Massachusetts
    • ,
  • Gary Bradwin

      Affiliations

    • Laboratory Medicine, Children's Hospital Boston, Boston, Massachusetts
    • ,
  • Carolyn Revta

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Julie Aldridge

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Vincent Ho

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Edwin Alyea

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • John Koreth

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Philippe Armand

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Robert Soiffer

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Jerome Ritz

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Paul G. Richardson

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Joseph H. Antin

      Affiliations

    • Division of Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Received 13 November 2009 ,Accepted 17 February 2010.

References 

  1. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008;41:229–237
  2. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112:4425–4431
  3. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292:2727–2734
  4. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:551–557
  5. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109:3108–3114
  6. Jones RJ, Lee KS, Beschorner WE, et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–783
  7. Park YD, Yasui M, Yoshimoto T, et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant. 1997;19:915–920
  8. Salat C, Holler E, Kolb HJ, et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood. 1997;89:2184–2188
  9. Kaleelrahman M, Eaton JD, Leeming D, et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF). Hematology. 2003;8:91–95
  10. Gerecitano J, Mathias C, Mick R, et al. Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation. J Hematother Stem Cell Res. 2003;12:215–223
  11. Scrobohaci ML, Drouet L, Monem-Mansi A, et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63:509–519
  12. Lee JH, Lee KH, Kim S, et al. Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant. 1998;22:883–888
  13. Faioni EM, Krachmalnicoff A, Bearman SI, et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of veno-occlusive disease of the liver. Blood. 1993;81:3458–3462
  14. Tanikawa S, Mori S, Ohhashi K, et al. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study. Bone Marrow Transplant. 2000;26:881–886
  15. Park YD, Yoshioka A, Kawa K, et al. Impaired activity of plasma von Willebrand factor–cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant. 2002;29:789–794
  16. Collins PW, Gutteridge CN, O'Driscoll A, et al. von Willebrand factor as a marker of endothelial cell activation following BMT. Bone Marrow Transplant. 1992;10:499–506
  17. Catani L, Gugliotta L, Vianelli N, et al. Endothelium and bone marrow transplantation. Bone Marrow Transplant. 1996;17:277–280
  18. Sudhoff T, Heins M, Sohngen D, et al. Plasma levels of D-dimer and circulating endothelial adhesion molecules in veno-occlusive disease of the liver following allogeneic bone marrow transplantation. Eur J Haematol. 1998;60:106–111
  19. Imanishi T, Kobayashi K, Kuki S, et al. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis. 2006;189:288–296
  20. Iguchi A, Kobayashi R, Yoshida M, et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant. 2001;27:1173–1180
  21. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant. 2005;5:2441–2447
  22. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–4343
  23. Benimetskaya L, Wu S, Voskresenskiy AM, et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood. 2008;112:4343–4352

 Financial disclosure: See Acknowledgments on page 1184.

PII: S1083-8791(10)00087-X

doi: 10.1016/j.bbmt.2010.02.016

Biology of Blood and Marrow Transplantation
Volume 16, Issue 8 , Pages 1180-1185 , August 2010

Article Tools

* Image Usage & Resolution